Vesterqvist O - Search Results

1

Pharmacodynamics and Pharmacokinetics of Irbesartan in Patients With Mild to Moderate Hypertension.

Marino MR, Langenbacher KM, Ford NF, Raymond RH, Manning J, Vesterqvist O, Shamblen EC, Lasseter KC. Marino MR, et al. Among authors: vesterqvist o. J Cardiovasc Pharmacol Ther. 1999 Apr;4(2):67-75. doi: 10.1177/107424849900400201. J Cardiovasc Pharmacol Ther. 1999. PMID: 10684525

2

Omapatrilat in patients with hepatic cirrhosis. Pharmacodynamics and pharmacokinetics.

O'Grady P, Vesterqvist O, Malhotra B, Manning J, Jemal M, Ge G, Mangold B. O'Grady P, et al. Among authors: vesterqvist o. Eur J Clin Pharmacol. 2001 Jun;57(3):249-57. doi: 10.1007/s002280100291. Eur J Clin Pharmacol. 2001. PMID: 11497341

3

Omapatrilat: neurohormonal and pharmacodynamic profile when administered with furosemide.

Uderman H, Vesterqvist O, Manning J Jr, Ferreira I, Delaney C, Liao WC. Uderman H, et al. Among authors: vesterqvist o. J Clin Pharmacol. 2001 Dec;41(12):1291-300. doi: 10.1177/00912700122012878. J Clin Pharmacol. 2001. PMID: 11762556 Clinical Trial.

4

Pharmacodynamics and pharmacokinetics of omapatrilat in heart failure.

Kostis JB, Klapholz M, Delaney C, Vesterqvist O, Cohen M, Manning JA Jr, Jemal M, Kollia GD, Liao WC. Kostis JB, et al. Among authors: vesterqvist o. J Clin Pharmacol. 2001 Dec;41(12):1280-90. doi: 10.1177/00912700122012869. J Clin Pharmacol. 2001. PMID: 11762555 Clinical Trial.

5

Effects of age and gender on the pharmacodynamics of omapatrilat in healthy volunteers.

Liao W, Vesterqvist O, Manning J Jr, Hammett JL, Ferreira IM, Meier A, Davis KD, Hutman HW. Liao W, et al. Among authors: vesterqvist o. Am J Geriatr Cardiol. 2001 Jan-Feb;10(1):50-4. doi: 10.1111/j.1076-7460.2001.90856.x. Am J Geriatr Cardiol. 2001. PMID: 11413936

6

Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor, omapatrilat in healthy subjects.

Liao WC, Vesterqvist O, Delaney C, Jemal M, Ferreira I, Ford N, Swanson B, Uderman H. Liao WC, et al. Among authors: vesterqvist o. Br J Clin Pharmacol. 2003 Oct;56(4):395-406. doi: 10.1046/j.1365-2125.2003.01888.x. Br J Clin Pharmacol. 2003. PMID: 12968984 Free PMC article. Clinical Trial.

7

Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients.

Campese VM, Lasseter KC, Ferrario CM, Smith WB, Ruddy MC, Grim CE, Smith RD, Vargas R, Habashy MF, Vesterqvist O, Delaney CL, Liao WC. Campese VM, et al. Among authors: vesterqvist o. Hypertension. 2001 Dec 1;38(6):1342-8. doi: 10.1161/hy1201.096569. Hypertension. 2001. PMID: 11751715 Clinical Trial.

8

Effect of the phospholipase A2 inhibitors quinacrine and 7,7-dimethyleicosadienoic acid in isolated globally ischemic rat hearts.

Sargent CA, Vesterqvist O, McCullough JR, Ogletree ML, Grover GJ. Sargent CA, et al. Among authors: vesterqvist o. J Pharmacol Exp Ther. 1992 Sep;262(3):1161-7. J Pharmacol Exp Ther. 1992. PMID: 1382129

9

Pharmacodynamic effects of dual neutral endopeptidase-angiotensin-converting enzyme inhibition versus angiotensin-converting enzyme inhibition in humans.

Massien C, Azizi M, Guyene TT, Vesterqvist O, Mangold B, Ménard J. Massien C, et al. Among authors: vesterqvist o. Clin Pharmacol Ther. 1999 Apr;65(4):448-59. doi: 10.1016/S0009-9236(99)70140-2. Clin Pharmacol Ther. 1999. PMID: 10223783 Clinical Trial.

10

Myocardial calcium-independent phospholipase A2 activity during global ischemia in isolated rabbit hearts.

Vesterqvist O, Sargent CA, Grover GJ, Ogletree ML. Vesterqvist O, et al. Cardiovasc Res. 1996 Jun;31(6):932-40. Cardiovasc Res. 1996. PMID: 8759249

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

70 results

Search Page

Filters